Hi, I’m Brad—founder of Sengi
A Clinical Research Organization that specializes in investigator-initiated trials in eye care.
I love what I do. I work directly with ophthalmologists and optometrists to turn their research ideas into published studies—faster, easier, and with greater impact.
With over a decade in ophthalmic clinical research and 50+ peer-reviewed publications, I bring both technical depth and strategic insight to every project. Whether you’re navigating your first IRB submission or aiming to publish in a top-tier journal, I help move your study from concept to completion—without unnecessary delays.
I love what I do. I work directly with ophthalmologists and optometrists to turn their research ideas into published studies—faster, easier, and with greater impact.
With over a decade in ophthalmic clinical research and 50+ peer-reviewed publications, I bring both technical depth and strategic insight to every project. Whether you’re navigating your first IRB submission or aiming to publish in a top-tier journal, I help move your study from concept to completion—without unnecessary delays.
Clinical research made accessible
At Sengi, we believe clinical research should be more accessible to practicing clinicians—not just academic centers or large sponsors. You see real-world problems and unmet needs every day. You should be empowered to study them.
Our mission is simple
To simplify clinical research because we believe that more doctors doing good research leads to better medical care for everyone.
The Problem We Solve
After supporting dozens of investigator-sponsored studies, we’ve seen three persistent challenges eye care professionals face:
Overworked
Clinic demands crowd out grant writing, IRB submissions, and publishing—delays that cost funding and podium opportunities.
Data blind spots
Limited tools and complex analyses turn results into guesswork—wasting resources and risking sub-optimal clinical decisions and outcomes.
Under-differentiated
In a saturated market, lack of visible research reduces recognition, referrals, and ability to recruit top talent—threatening growth.
Sengi exists to change that—with clear guidance, efficient systems, and end-to-end execution that turns data into decisions, submissions into approvals, and studies into recognition.
Now, that same approach is captured in Eye-dea to Impact—Dr. Brad Hall’s hands-on guide to running investigator-initiated trials without slowing down your practice.
Our Approach: Making Research Accessible
Our signature framework is built for the realities of busy eye care professionals. We simplify trial operations, bring clarity to your data, and elevate your professional visibility.
We’ve supported studies funded by leading ophthalmic sponsors—including Alcon, Johnson & Johnson, and Topcon—but our focus is always on you, the investigator.
Whether you’re running your first single-site study or preparing your next submission, we help you move forward faster, with structure, insight, and confidence.
